Arcellx Inc - ACLX Future Profit

Corporate emblem and logo of Arcellx (ACLX)

Arcellx develops advanced ddCAR technologies to combat hematological malignancies by investing in scientific potential. However, the lack of commercial products and reliance on external financing create significant risks during clinical trials. High demand for CAR-T therapy sustains interest in the asset. The financial forecast reflects market expectations, where the mark serves as a relevant indicator.

ACLX: Arcellx Expected Profit 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Arcellx Inc (ACLX)

- price and consensus price forecast:
Price Chart Arcellx|ACLX - Fair Value Consensus
- issuer market value details:
Market Valuation Arcellx|ACLX - Value Adjusted for Debt and Cash
- book capitalization information:
Book Value per Share Arcellx|ACLX - Company Book Value|Market Value to Book Value Ratio arcellx.com|ACLX - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Arcellx|ACLX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Arcellx Corp|ACLX - Company Cumulative Debt|Debts to Book Capitalization Arcellx|ACLX - Company Long-Term Indebtedness|Company Short-Term Debts Arcellx|Quick Liquidity arcellx.com
- earnings and valuation multiples information:
ACLX - Final Profit|Projected Future Earnings Arcellx|ACLX - Price to Earnings Ratio|Forward P/E Multiple Arcellx, Inc.|ACLX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcellx|ACLX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Arcellx|ACLX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months arcellx.com|ACLX - Earnings per share growth this year|Earnings growth forecast for next year Arcellx
- company sales and revenue statistics:
ACLX - Revenue and Sales Volume|Projected Sales Volume Arcellx|ACLX - Market Cap to Revenue|Price-to-Projected Revenue Ratio Arcellx
Fundamental company analysis:Arcellx, ACLX
Core merchandise of Arcellx Corp

To protect capital, investors analyze discounted market expectations, identifying hidden costs through the dynamics of future earnings. In the case of Arcellx (ACLX), the projected financial return reflects the probability of CAR-T therapy commercialization and M&A potential, where the bullish trend confirms the efficacy of clinical trials, while peak values signal the risk of overpaying for optimism already priced in.

Competing companies

Expected Profit TG Therapeutics, Inc.|IRON: Expected Net Income|Future Profit SNDX (Syndax Pharmaceuticals, Inc.)|KURA (Kura Oncology Inc) - Expected Net Income|Projected Future Earnings ADCT (ADC Therapeutics Corp)|Foghorn Therapeutics, Inc. - Expected Profit|VOR - Expected Profit|NKTX: Expected Profit|coeptistx.com (COEP) - Expected Profit|Expected Net Profit Actinium Pharma (ATNM)|Expected Profit Estrella Bio|Expected Net Profit CASI Pharmaceuticals, Inc CASI|Projected Future Earnings MRKR|in8bio.com - Net Profit Forecast|Projected Future Earnings ERNA (Eterna Therapeutics Inc.)|Projected Future Earnings GT Biopharma Inc GTBP|APTO - Expected Profit|Expected Net Income BPTH (Bio-Path Holdings, Inc)|MEIP: Projected Future Earnings|Future Profit Vincerx Pharma